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A B S T R A C T
Amyloid imaging is a valuable tool for research and diagnosis in dementing disorders. Successful use of this tool
is limited by the lack of a common standard in the quantiﬁcation of amyloid imaging data. The Centiloid ap-
proach was recently proposed to address this problem and in this work, we report our implementation of this
approach and evaluate the impact of diﬀerences in underlying image analysis methodologies using both cross-
sectional and longitudinal datasets. The Centiloid approach successfully converts quantitative amyloid burden
measurements into a common Centiloid scale (CL) and comparable dynamic range. As expected, the Centiloid
values derived from diﬀerent analytical approaches inherit some of the inherent beneﬁts and drawbacks of the
underlying approaches, and these diﬀerences result in statistically signiﬁcant (p < 0.05) diﬀerences in the
variability and group mean values. Because of these diﬀerences, even after expression in CL, the 95% speciﬁcity
amyloid positivity thresholds derived from diﬀerent analytic approaches varied from 5.7 CL to 11.9 CL, and the
reliable worsening threshold varied from −2.0 CL to 11.0 CL. Although this diﬀerence is in part due to the
dependency of the threshold determination methodology on the statistical characteristics of the measurements.
When amyloid measurements obtained from diﬀerent centers are combined for analysis, one should not expect
Centiloid conversion to eliminate all the diﬀerences in amyloid burden measurements due to variabilities in
underlying acquisition protocols and analysis techniques.
1. Introduction
Alzheimer's disease (AD) is the most common form of dementia
(Holtzman et al., 2011) and the prevalence of AD is expected to increase
dramatically within the next 50 years (Alzheimer's, 2014). Currently,
there are no proven disease-modifying treatments (Aisen, 2009; Aisen
et al., 2011; Doody et al., 2013; Huang and Mucke, 2012); further re-
search and development are in urgent need to prevent and/or treat this
disease. It is well established that AD pathologies including amyloid
plaques and neuroﬁbrillary tangles begin to accumulate well before
clinical symptoms appear (Bateman et al., 2012; Benzinger et al., 2013;
Holtzman et al., 2011; Jack et al., 2010; Jansen et al., 2015; Morris and
Price, 2001). Therefore, there is an increasing consensus that early
intervention is necessary to eﬀectively treat AD or slow down its pro-
gression (Aisen, 2009; Aisen et al., 2011). To enable the design of
therapeutic trials, especially in asymptomatic individuals, validated
surrogate biomarkers for AD pathology are necessary (Aisen, 2009;
Aisen et al., 2011). As the primary pathological process in AD, accurate
assessment of amyloid deposition in the brain may serve as an eﬀective
biomarker for the investigation of AD and marker in treatment trials.
To achieve this goal, positron emission tomography (PET) imaging
tracers such as [11C]Pittsburgh Compound-B (PiB) (Klunk et al., 2004),
[18F]ﬂorbetapir (Wong et al., 2010), [18F]ﬂorbetaben (Rowe et al.,
2008) and [18F]ﬂutemetamol (Vandenberghe et al., 2010), were de-
veloped to enable in vivo measurement of ﬁbrillar beta-amyloid (Aβ)
deposition. However, diﬀerences in these imaging tracers can lead to
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diﬀerent estimations of the amyloid burden in the brain (Klunk et al.,
2015; Landau et al., 2013). In addition to tracer diﬀerences, there is
also substantial variability in the methods diﬀerent groups use to
quantify amyloid burden (Su et al., 2016), leading to diﬃculties in
comparing and interpreting numeric results reported from diﬀerent
groups (Klunk et al., 2015).
To address these issues and facilitate standardization of PET based
amyloid burden measurements, the Centiloid Working Group outlined
the procedures for establishing the Centiloid scale and converting group
speciﬁc amyloid burden measurements into the standard scale (Klunk
et al., 2015). This group also made the dataset used for deﬁning the
Centiloid scale publicly available at the Global Alzheimer's Association
Information Network (GAAIN; http://www.gaain.org). In this ap-
proach, two anchor points were used to deﬁne the Centiloid scale: the
mean amyloid burden of the young control (YC) group who are as-
sumed to have no amyloid pathology in their brain (deﬁned as 0 in the
Centiloid scale) and the mean amyloid burden of the AD group in the
GAAIN dataset (deﬁned as 100 in the Centiloid scale). A standard image
analysis procedure estimating the standard uptake value ratio (SUVr) of
a global cortical target region (CTX) over whole cerebellum (WC) for
PiB PET images acquired within the 50 to 70min post-injection time
window was described to calculate the standard Centiloid SUVr, which
was then mapped to the Centiloid scale based on the two anchor points.
The outcome measure of any other analysis techniques can then be
converted to the Centiloid scale using a linear transformation based on
the GAAIN dataset (or other datasets that meets the criteria for Cen-
tiloid calibration), i.e. level-2 calibration (Klunk et al., 2015). The in-
itial Centiloid paper also described the requirements and steps to scale
amyloid burden measurements obtained using other PET tracers to the
Centiloid scale (Klunk et al., 2015). Since its inception, the research
community has gradually adopted the Centiloid approach (Jack et al.,
2017; Leuzy et al., 2016; Weiner et al., 2017), and calibrations of [18F]-
NAV4694 (Rowe et al., 2016) and [18F]-ﬂorbetaben (Rowe et al., 2017)
based amyloid burden measurements to the Centiloid scale have been
published recently.
The goal of the Centiloid scale is to standardize PET based amyloid
burden measurements to make comparisons of results from diﬀerent
research groups easier and facilitate the use of amyloid PET imaging as
a diagnostic tool. However, it remains unknown how comparable
Centiloid values derived from diﬀerent analysis pipelines are, and what
the impact of variability in the implementation of Centiloid analysis
will be to cross-sectional and longitudinal studies. To answer these
questions, we compared Centiloid values obtained from diﬀerent ana-
lysis techniques using the GAAIN dataset and PiB PET imaging data
from Knight Alzheimer Disease Research Center (ADRC) Memory and
Aging Project. Speciﬁcally, 1) the GAAIN dataset was used to establish
Centiloid conversion equations for 13 diﬀerent methods to quantify
global amyloid burden using PiB PET and then used to compare the
variability of the measured amyloid burden within young controls who
have no amyloid in their brain; 2) the impact of quantiﬁcation methods
to cross-sectional amyloid burden measurements after the Centiloid
conversion was further evaluated in the Knight ADRC cohort; 3) long-
itudinal Knight ADRC data was used to examine the variability of
amyloid burden measurements and assess the sensitivity to longitudinal
changes in amyloid burden; and ﬁnally 4) we estimated amyloid posi-
tivity threshold in Centiloid scale and compared the thresholds ob-
tained from diﬀerent quantiﬁcation methods.
2. Methods
2.1. Participants
The dataset used to deﬁne the Centiloid scale (downloaded from the
GAAIN website: http://www.gaain.org) consists of 34 YCs
(age≤ 45 yrs) and 45 clinically diagnosed AD patients ages 50 to 89
who had a clinical dementia rating (CDR) (Morris, 1993)> 0. A subset
(GAAIN_SUB) of the GAAIN dataset (18 YCs and 18 ADs) had suﬃcient
dynamic PiB PET data to allow all of our analysis techniques (e.g.,
binding potential calculation) to be performed. These numbers ex-
ceeded the number of participants recommended by the Centiloid
working group for level-2 calibration (Klunk et al., 2015)) and were
successfully processed with our local processing pipeline (Su et al.,
2015; Su et al., 2013) and passed quality control.
The Knight ADRC cohort included 590 participants with at least a
single PiB PET session, with a mean age of 67.7 ± 10.0 yrs., 37.6%
APOE4 carriers, and 91 of them were CDR positive (> 0). A subset of
243 participants had two longitudinal PiB PET data points with a mean
baseline age of 65.8 ± 9.4 yrs., 32.5% of them were APOE4 carriers,
and 16 of them were CDR positive. The mean follow-up interval was
3.2 ± 1.5 yrs.
2.1.1. Ethics statement
All assessment and imaging procedures were approved by
Washington University's Human Research Protection Oﬃce. Written
informed consent was obtained from all individuals or their authorized
representatives.
2.2. Imaging
The imaging protocols for the GAAIN dataset have been described
previously (Klunk et al., 2015). The PiB PET from the GAAIN dataset
includes PET images acquired within the 50–70min post-injection
window at a minimum. The GAAIN_SUB dataset had full dynamic multi-
frame PET imaging data acquired between 0 and 70min after injection
of PiB. T1-weighted MRI was also available to provide anatomical in-
formation and facilitate PET quantiﬁcation.
For the Knight ADRC cohort, dynamic PET imaging was conducted
for 1 h with a Siemens/CTI EXACT HR+ scanner or a Biograph 40 PET/
CT scanner (Siemens Medical Solutions, Erlangen, Germany) in three-
dimensional mode after intravenous administration of approximately
12mCi of PiB. Anatomic MRI was acquired with a T1-weighted mag-
netization-prepared rapid gradient echo (MPRAGE) sequence using a
Siemens 1.5 T or 3 T scanner.
2.3. Image analysis
Standard Centiloid processing was performed on the GAAIN dataset
as described in the initial Centiloid paper (Klunk et al., 2015). In
summary, a summed PET image of the 50–70min post-injection
window was created from raw PET data. Both PET and MRI data for
each subject were re-oriented to match the Montreal Neurological In-
stitute (MNI)-152 T1-weighted template provided with the Statistical
Parametric Mapping version 8 (SPM8) software (Ashburner, 2009).
Subjects' MRIs were then coregistered to the MNI template and subse-
quently, the PET images were coregistered to the individual MRI.
Spatial normalization was performed using the uniﬁed segmentation
method (Ashburner and Friston, 2005) implemented in SPM8 to allow
quantiﬁcation in the MNI-152 atlas space. Standard Centiloid SUVr was
calculated based on the CTX region and WC region described in (Klunk
et al., 2015).
In addition to standard Centiloid processing, our local processing
pipeline (PUP; https://github.com/ysu001/PUP) was also used to pro-
cess the GAAIN_SUB dataset and Knight ADRC data. Details of PUP
processing have been discussed previously (Su et al., 2015; Su et al.,
2013). Standard FreeSurfer (v5.3; Martinos Center for Biomedical
Imaging, Charlestown, Massachusetts, USA; https://surfer.nmr.mgh.
harvard.edu/fswiki) based PUP processing (Su et al., 2015; Su et al.,
2013) includes scanner resolution harmonization ﬁlter (Joshi et al.,
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2009), inter-frame motion correction, PET-MR registration, regional
time-activity curves extraction, regional spread function (RSF) based
partial volume correction (PVC) (Rousset et al., 2008; Su et al., 2015),
binding potential estimated using Logan graphical analysis (BPND)
(Logan et al., 1996), and SUVr analysis. Cerebellar cortex was used as
the default reference region for BPND and SUVr analysis with 30–60min
post-injection as the standard time window. As the global index of
amyloid burden, a mean cortical binding potential (Mintun et al., 2006)
or mean cortical SUVr was calculated based on a selected set of Free-
Surfer-deﬁned frontal, parietal, temporal and precuneus cortical re-
gions (Su et al., 2013).
2.4. Quantiﬁcation methods
In this study, a total of 13 diﬀerent quantiﬁcation methods were
implemented to quantify amyloid burden (summarized in Table 1). In
addition to the standard Centiloid processing described in the previous
section, 12 additional methods were included in this study that varied
in 1) quantitative metric, i.e. BPND vs. SUVr; 2) with or without RSF
PVC; 3) reference regions, i.e. cerebellar cortex, brain stem, or whole
cerebellum; 4) post-injection time window, i.e. 30–60min vs.
40–70min. The inclusion of various methods was motivated by several
observations. Firstly, it has been suggested (van Berckel et al., 2013)
that a more quantitative measurement such as BPND was more reliable
in assessing amyloid burden than the commonly used SUVr measur-
ements–although such a measurement requires longer scans and more
complicated modeling. Secondly, whether PVC is beneﬁcial to amyloid
PET quantiﬁcation remains a question of debate. For example, while we
reported improved sensitivity to amyloid burden changes when RSF
PVC was used (Su et al., 2015), another group did not observe the same
beneﬁt when using a similar PVC technique (Schwarz et al., 2016).
Thirdly, it has been suggested that alternative reference regions may be
more appropriate under various circumstances (Bateman et al., 2012;
Benzinger et al., 2013; Edison et al., 2012) and may lead to better
sensitivity to changes in amyloid burden (Chen et al., 2015; Schwarz
et al., 2016; Su et al., 2016). Therefore, SUVr analysis was also per-
formed using brainstem and whole cerebellum as the reference. Finally,
due to diﬀerences in PET imaging protocols, diﬀerent studies diﬀer in
the post-injection time window than what is available for analysis. For
example, for the Knight ADRC cohort, PiB PET imaging stops at 60min
post-injection, while for the Dominantly Inherited Alzheimer's Network
(DIAN) study (Morris et al., 2012), PiB PET data in the 40–70min post-
injection window is the standard. Therefore, analyses using both
30–60min and 40–70min post-injection window were performed for
the GAAIN_SUB dataset.
Based on the GAAIN_SUB dataset, Centiloid conversion equations
were generated according to the level-2 analysis guidelines described in
the initial Centiloid paper (Klunk et al., 2015) for each version of the
global amyloid burden index generated by our local analysis pipeline.
Estimated amyloid burdens were then converted into Centiloid units
(CL) for each variation of the global amyloid index for both GAAIN_SUB
dataset and ADRC data using those equations. Knight ADRC data was
not processed with the standard Centiloid procedure because of the lack
of PET data between 60 and 70min post-injection.
2.5. Amyloid positivity thresholds
Three methods were used to deﬁne the thresholds for amyloid po-
sitivity in Centiloid scale. The ﬁrst method simply transformed the
empirical thresholds we have commonly used in the past, i.e. a mean
cortical BPND of 0.18 (Su et al., 2013; Vlassenko et al., 2011) and a
mean cortical SUVr_RSF of 1.42 (Sutphen et al., 2015; Vlassenko et al.,
2016), which was an equivalent threshold as the mean cortical
BPND=0.18, into CL by applying the conversion equation determined
in 2.3 & 2.4. The second method adopted the speciﬁcity thresholds
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measurements among the subset of YC participants in the GAAIN_SUB
dataset. The last method used a modiﬁed “reliable worsening” (RW)
approach (Jack et al., 2017), in which the threshold was deﬁned as the
amyloid burden at which the smoothed rate-of-change to baseline
amyloid burden curve went above zero after the curve passes the
minimum. The rate to baseline amyloid burden curve was generated
based on the ADRC longitudinal dataset. A locally weighted regression
method (LOESS) (Cleveland, 1979) was used to smooth the raw data,
and bootstrapping was performed to obtain the conﬁdence interval of
the LOESS curves. This modiﬁcation was necessary because using the
original RW approach (Jack et al., 2017) for some analysis techniques
we examined, the estimated threshold corresponds to a negative rate of
amyloid accumulation, which was against the deﬁnition of worsening
amyloid pathology (see Fig. 4 for an example).
2.6. Statistical analysis
The mean and standard deviation of the estimated amyloid burden
in CL for the YC participants (N=18) in the GAAIN_SUB dataset were
calculated and used to assess the inter-individual variability of PiB-PET
measure in healthy participants as an indicator of the reliability of the
amyloid burden measurements. A threshold (CL=10.7) was de-
termined based on the 99th percentile of CL value obtained using
FreeSurfer-deﬁned whole cerebellum as the reference region with no
partial volume correction, using 30–60min window and SUVr analysis
(CL_3060_SUVr_WC). This threshold was used to group Knight ADRC
participants into amyloid negative and amyloid positive groups for
additional analysis, and it was intentionally chosen to be diﬀerent from
the thresholds determined in 2.4 to avoid circularity. It was more
conservative than the conventional thresholds we used previously, i.e.
mean cortical BPND= 0.18 & mean cortical SUVr_RSF= 1.42, to
minimize the possibility of including participants who have very low
levels of amyloid. According to this threshold, the Knight ADRC long-
itudinal dataset has 182 stable amyloid negative participants who re-
mained amyloid negative at both baseline and follow-up, and 61 par-
ticipants (accumulators) were either amyloid positive at baseline or
converted to amyloid positive at follow-up. F-tests were used to de-
termine whether there were diﬀerences in the variability of amyloid
burden measurements obtained from two diﬀerent techniques. Paired t-
tests were used to determine whether there were signiﬁcant diﬀerences
in the mean CL values when diﬀerent analysis techniques were used.
The longitudinal data for stable amyloid negative participants in the
Knight ADRC cohort was assumed to have minimal changes in amyloid
burden in the follow up to assess the intra-individual variability of the
amyloid burden measurements. For amyloid accumulators in the
longitudinal Knight ADRC cohort (N=61), paired t-tests were used to
assess the signiﬁcance of longitudinal change, an eﬀect size measure
was also calculated as the ratio of annualized rate-of-change over intra-
individual variability estimated based on the amyloid negative parti-
cipants to assess the statistical power of CL derived from a particular
analysis technique. To assess the impact of the diﬀerence in statistical
power, similar to our previous study (Su et al., 2016), we also estimated
the number of participants per arm needed to detect a 50% reduction in
amyloid accumulation rate due to treatment with 80% power and a
two-tailed type-I error of p=0.05 in a hypothetical 12-month placebo-
controlled randomized clinical trial. A total of 84 hypothesis tests were
performed in our analysis, to account for multiple comparisons, an
overall signiﬁcance level was deﬁned as p < 0.0005 (i.e. after Bon-
ferroni correction of 100 comparisons), while a tentative signiﬁcance
level was set at p < 0.05 (i.e. without correction for multiple com-
parisons).
3. Results
3.1. Centiloid analysis in the GAAIN dataset
Our implementation of the standard Centiloid analysis generated
results in strong agreement with the published Centiloid measurements
for the GAAIN dataset (r2= 0.9996) (Supp. Fig. 1). The conversion
equations for the 12 diﬀerent implementations of PiB-PET analysis
techniques and details of the analysis results are given in the supple-
mentary material. Without the conversion, the amyloid burden mea-
surements obtained from diﬀerent quantiﬁcation methods varied in
numerical values and dynamic ranges and could not be directly com-
pared to each other (Fig.1A). The Centiloid conversion approach suc-
cessfully converted these diﬀerent measurements into approximately
the same scale (Fig. 1B). After the Centiloid conversion, the variability
across the YC group (VYC) was lower in general when RSF PVC was
applied, although it did not reach statistical signiﬁcance in some cases
(Table 2). Other comparisons of VYC for diﬀerent analysis techniques,
i.e. time window diﬀerences, SUVr vs BPND, and choice of reference
regions, in general did not reach signiﬁcance (Table 2). Diﬀerences in
analysis techniques (especially when diﬀerent time windows were used
for quantiﬁcation) also had an impact on the mean CL values for the YC
group and this was often ampliﬁed by RSF PVC (Table 2).
3.2. Cross-sectional knight ADRC cohort analysis
Results for the cross-sectional analysis of the Knight ADRC cohort
are summarized in Table 3 and Fig. 2. In this larger cohort, it was de-
monstrated that diﬀerences in analytic techniques could have a sig-
niﬁcant impact (with a few exceptions) to both the variability in the
Centiloid measurements, as well as group, mean values (Table 3,
Fig. 2).
3.3. Longitudinal knight ADRC cohort analysis
The results of the analysis of the longitudinal Knight ADRC cohort
are summarized in Table 4 and Fig. 3. Based on this analysis, applica-
tion of RSF PVC, in general, lead to lower intra-individual variability in
the amyloid-negative group (Fig. 3A) and larger eﬀect size in long-
itudinal changes in the amyloid-positive group. The lowest variability
in the amyloid-negative group (2.1 CL) was observed when binding
potential analysis with RSF PVC (CL_3060_BP_RSF) was used to quantify
amyloid burden with cerebellar gray matter referencing. The observed
annual changes in amyloid burden had the largest eﬀect size (1.9) when
brainstem was used as the reference region and SUVr analysis was
performed with RSF PVC (CL_3060_SUVr_RSF_BS). For this approach, its
largest observed measured annual change (5.2 Centiloid units) resulted
in the smallest sample size (N=17 per arm) in a hypothetical anti-
amyloid clinical trial that reduced the rate of amyloid accumulation by
50%, although the intra-individual variability was larger. All quantiﬁ-
cation methods detected longitudinal accumulation (p < 0.0005) of
amyloid in the amyloid positive group.
3.4. Amyloid positivity thresholds
When the Centiloid conversion is applied to empirical amyloid po-
sitivity thresholds our group has previously used, a mean cortical BPND
threshold of 0.18 is transformed into 18.2 CL, and a mean cortical
SUVr_RSF threshold of 1.42 is transformed into 16.4 CL. The speciﬁcity
approach based amyloid positivity thresholds are listed in Tables 2 & 3,
and the thresholds were in the range of 6–12 Centiloid units. The
procedure for the determination of RW threshold is illustrated in Fig. 4.
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The modiﬁed RW approach based thresholds are listed in Table 3 and
varied from −2.0 to 11.0 CL. These RW thresholds were all integer
values because we only sampled the rate versus baseline amyloid
burden curves at integer CLs. Both the speciﬁcity and the RW based
approaches generated thresholds that were more sensitive (i.e. lower in
Centiloid units) than our empirical thresholds, which were more geared
toward separation of clinical AD patients from the general population.
The speciﬁcity and RW based thresholds in relation to the distribution
of amyloid burden in the Knight ADRC cohort are displayed in Fig. 5 for
two example analytic approaches. Using the lowest threshold in CL
(−2.0 for CL_3060_SUVr_BS determined with the RW approach), 46%
of the cognitively normal participants in their 70s were classiﬁed as
amyloid positive; and with a threshold of 11.9 CL (determined using the
speciﬁcity approach for CL_SUVr_BS), 36% of the cognitive normal 70-
year-olds were classiﬁed as amyloid positive. In comparison, an 18.2 CL
threshold derived from our empirical approach resulted in 33% of the
cognitively normal 70-year-olds classiﬁed as amyloid positive.
4. Discussion
The Centiloid approach is proposed and designed to standardize
PET based amyloid burden measurements and the original Centiloid
Fig. 1. Box plot of amyloid burden measurements for the GAAIN dataset before (A) and after (B) converting to the Centiloid scale. YC data are shown in black and AD
data are shown in red. The same 13 versions of the amyloid burden measurements summarized in Table 1 were included in this ﬁgure. Binding potential data are
presented as BP+ 1 in (A) to allow better comparison with SUVr measurements.
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Table 3

















A− Mean −0.6 1.7 0.1 −1.9 −6.4 −5.0 −3.4 −3.4
A− SD 4.7 3.2 5.4 4.0 7.0 5.1 5.1 4.0
A+ Mean 56.8 52.5 66.2 61.2 58.0 54.2 61.5 55.8
A+ SD 31.6 31.2 34.9 35.9 36.8 35.0 34.7 33.8
RW threshold
10.0 6.0 11.0 2.0 −2.0 −2.0 6.0 0.0
Speciﬁcity threshold (95%) (duplicated from Table 2)
9.2 7.1 9.8 6.2 11.9 10.2 7.5 6.7
Level of signiﬁcance
Inter-individual variability for amyloid negative (A−) participants




Comparison within A− group




Comparison within A+ group




ns: nonsigniﬁcant; ⁎: p < 0.05; ⁎⁎: p < 0.0005, therefore remain signiﬁcant after Bonferroni correction for multiple comparisons. The lower portion of the table
reports the signiﬁcance level for pair-wise comparison between diﬀerent quantiﬁcation techniques. For comparisons between RSF partial volume corrected methods
with their counterparts without RSF PVC (RSFvsNonRSF), the signiﬁcance level is reported under the RSF column; for comparisons between brainstem referencing
methods with their counterparts with the default cerebellar gray referencing (BSvsCER), the signiﬁcance level is reported under the BS column; for comparisons
between whole cerebellum referencing methods with their counterparts with the default cerebellar gray matter referencing (WCvsCER), the signiﬁcance level is
reported under the WC column; For time window comparison (4070vs3060), the signiﬁcance level is reported under the 4070 column; for comparison between SUVr
and BP measurements (SUVrvsBP), the signiﬁcance level is reported under the SUVr column. It should be noted that comparison for a particular technical variability
was only performed between otherwise equivalent techniques.
Table 2



























YC mean −0.1 0.0 1.6 0.0 1.2 −0.3 0.2 −0.2 0.3 −0.1 0.1 −0.4 0.1
YC SD 4.2 5.6 3.3 5.3 3.1 6.1 3.7 5.2 3.3 7.3 6.1 4.8 4.0
AD mean 102.9 102.8 101.2 102.8 101.6 103.1 102.6 103.0 102.5 102.9 102.7 103.2 102.7
R2 0.96 0.94 0.97 0.95 0.98 0.98 0.99 0.98 0.98 0.97 0.98 0.97
Speciﬁcity threshold (95%)
6.8 9.2 7.1 8.7 6.2 9.8 6.2 8.3 5.7 11.9 10.2 7.5 6.7
Level of signiﬁcance
Inter-individual variability
RSFvsNonRSF ⁎ ⁎ ⁎ ns ns ns
BSvsCER ns ⁎
WCvsCER ns ns
4070vs3060 ns ns ns ns
SUVrvsBP ns ns ns ns
Comparison of YC mean
RSFvsNonRSF ns ns ns ns ns ns
BSvsCER ns ns
WCvsCER ns ns
4070vs3060 ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎
SUVrvsBP ns ⁎ ns ⁎
ns: nonsigniﬁcant; ⁎: p < 0.05; ⁎⁎: p < 0.0005, therefore remain signiﬁcant after Bonferroni correction for multiple comparisons. The lower portion of the table
reports the signiﬁcance level for pair-wise comparison between diﬀerent quantiﬁcation techniques. For comparisons between RSF partial volume corrected methods
with their counterparts without RSF PVC (RSFvsNonRSF), the signiﬁcance level is reported under the RSF column; for comparisons between brainstem referencing
methods with their counterparts with the default cerebellar gray referencing (BSvsCER), the signiﬁcance level is reported under the BS column; for comparisons
between whole cerebellum referencing methods with their counterparts with the default cerebellar gray matter referencing (WCvsCER), the signiﬁcance level is
reported under the WC column; For time window comparison (4070vs3060), the signiﬁcance level is reported under the 4070 column; for comparison between SUVr
and BP measurements (SUVrvsBP), the signiﬁcance level is reported under the SUVr column. It should be noted that comparison for a particular technical variability
was only performed between otherwise equivalent techniques.
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paper suggested ﬁve beneﬁts that widespread use of the Centiloid ap-
proach would bring: 1) facilitation of direct comparisons of results
across diﬀerent research groups when methods and tracers are in-
volved; 2) a clear deﬁnition of amyloid positivity thresholds; 3) further
deﬁnition of meaningful amyloid burden ranges; 4) an expression of
longitudinal changes in standard units; 5) direct comparisons of the
characteristics of diﬀerent tracers (Klunk et al., 2015). As amyloid PET
tracers are designed for in vivo measurement of the underlying amyloid
pathology, studies have found a good correlation between PET mea-
surement and post-mortem pathology (Clark et al., 2011; Ikonomovic
et al., 2008). Therefore, the Centiloid approach allows intuitive inter-
pretation of the amyloid burden measurements in the Centiloid scale.
For example, a 20 CL would indicate the participant had approximately
20% amyloid plaque density of an average AD patient. To assess whe-
ther the proposed beneﬁts of the Centiloid approach are achievable, we
calibrated 13 versions of PiB PET analysis techniques following the
Centiloid working group's recommendation and then examined the
impact of variations in analytic approach to the signal to noise ratio and
sensitivity of the estimated brain amyloid burden after they were con-
verted into CL. Thresholds for amyloid positivity in CL were also de-
termined using three diﬀerent approaches.
As demonstrated in the original Centiloid paper (Klunk et al., 2015)
and replicated in our study, the Centiloid approach successfully nor-
malized the mean amyloid burden to approximately 0 for the YC group
and approximately 100 for the AD group for the GAAIN dataset re-
gardless which quantiﬁcation method is used (Table 2, Fig. 1). When
applied to the larger Knight ADRC cohort, the measured amyloid
burden ranges from approximately 0 CL in amyloid negative partici-
pants to an average of about 60 CL in amyloid positive participants for
all methods compared (Table 3). However, when tested statistically,
diﬀerences can be detected in both mean amyloid burden and varia-
bility when diﬀerent quantiﬁcation methods are adopted even after
conversion to the Centiloid scale. It was observed in the Knight ADRC
data that the peak distribution of the Centiloid measure (Fig. 5) and the
average for amyloid negative participants (Table 3) were below zero CL
for many analysis methods. While this might be partly attributable to
Fig. 2. Comparison of inter-individual variability of measured amyloid burden (A, B), mean amyloid burden in people with minimal amyloid burden (C, D), and in
people with substantial amyloid (E, F), for diﬀerent quantiﬁcation methods, i.e. with or without partial volume correction (A, C, E), and using diﬀerent reference
region (B, D, F). RSF: Regional spread function based partial volume correction; NonRSF: without partial volume correction; **signiﬁcant diﬀerence (p < 0.0005)
that survives Bonferroni correction for multiple comparisons. The analysis was based on the cross-sectional analysis of Knight ADRC data.
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selection bias, as we ﬁrst used a threshold to deﬁne amyloid positivity
that biased the average amyloid burden measurement toward the lower
end, the primary reason for this phenomenon was likely due to the
diﬀerences in nonspeciﬁc binding of the tracer and tracer delivery
diﬀerences between younger controls and older controls. These ob-
servations suggest that, with the current approach to generate amyloid
burden measurements in the Centiloid scale, the proposed beneﬁts 1
and 4 can be achieved on a qualitative level while statistically detect-
able diﬀerences exist and need to be addressed. As an example, if we
want to compare the amyloid burden of a sporadic AD population
(Knight ADRC) to the amyloid burden of autosomal dominant AD po-
pulation in the DIAN cohort, statistical diﬀerence due to the diﬀerence
in imaging protocol can be expected, i.e. 30–60min post-injection
window in Knight ADRC vs. 40–70min post-injection window in DIAN,
even after conversion into the Centiloid scale. It should be noted that
this diﬀerence may be caused in part by the relatively small sample size
of the calibration dataset to generate the Centiloid conversion equa-
tions.
As a biomarker for amyloid pathology, the imaging based con-
tinuous measure of amyloid burden was often dichotomized into
normal or abnormal based on a threshold for clinical diagnosis/staging
of AD (Jack et al., 2011; Sperling et al., 2011), as eligibility criteria for
clinical trials (Hampel et al., 2015; Sperling et al., 2014), and to
facilitate research (Jack et al., 2016; Vlassenko et al., 2016). In this
study, we determined amyloid positivity thresholds in CL using three
diﬀerent approaches. Although, there was substantial variability in the
numerical values of Centiloid thresholds for amyloid positivity, the
percentage of cognitively normal participants in their 70s classiﬁed as
amyloid positive only range moderately from 33% to 46%. We did not
observe a very high (and probably unrealistic) amyloid positivity per-
centage of 75% when the speciﬁcity approach was used to deﬁne the
threshold as Jack et al. (Jack et al., 2017) reported. In general, the
speciﬁcity-based thresholds were typically higher than the RW based
thresholds (Table 3, Fig. 5) contrary to what Jack et al. reported with a
speciﬁcity threshold of 8 CL and an RW threshold of 19 CL (Jack et al.,
2017). These discrepancies might be a consequence of the analysis
methods that were chosen to quantify amyloid as well as diﬀerences in
the study cohorts and highlight the caution necessary for adopting a
threshold obtained from a diﬀerent processing method. This study de-
monstrates that the thresholds for amyloid positivity in CL were im-
plementation dependent, especially when the RW method was used to
determine the threshold. For example, when brainstem was used as the
reference, the amyloid positivity threshold was−2.0 CL, and if we use
this threshold on the GAAIN dataset quantiﬁed using the standard
Centiloid processing, 20 of the 34 young controls would be classiﬁed as
amyloid positive which was apparently incorrect. Therefore, the
Table 4

















Intra-individual variability 2.8 2.1 3.1 2.6 3.6 2.7 3.0 2.4
Annualized rate of change in A+ group 3.5 3.7 3.9 4.4 5.1 5.2 4.0 4.3
Eﬀect size of annual change 1.3 1.8 1.2 1.7 1.4 1.9 1.3 1.8
Sample size (50% reduction in rate) 51 31 70 45 30 17 58 31
Level of signiﬁcance
Longitudinal change in A+ group ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎ ⁎⁎
Test of intra-individual variability




ns: nonsigniﬁcant; ⁎: p < 0.05; ⁎⁎: p < 0.0005, therefore remain signiﬁcant after Bonferroni correction for multiple comparisons. For comparisons between RSF
partial volume corrected methods with their counterparts without RSF PVC (RSFvsNonRSF), the signiﬁcance level is reported under the RSF column; for comparisons
between brainstem referencing methods with their counterparts with the default cerebellar gray referencing (BSvsCER), the signiﬁcance level is reported under the
BS column; for comparisons between whole cerebellum referencing methods with their counterparts with the default cerebellar gray matter referencing (WCvsCER),
the signiﬁcance level is reported under the WC column; For time window comparison (4070vs3060), the signiﬁcance level is reported under the 4070 column; for
comparison between SUVr and BP measurements (SUVrvsBP), the signiﬁcance level is reported under the SUVr column. It should be noted that comparison for a
particular technical variability was only performed between otherwise equivalent techniques.
Fig. 3. Comparison of the intra-individual variability of amyloid burden measurements for quantiﬁcation methods with and without partial volume correction (A),
and using diﬀerent reference region (B). RSF: Regional spread function based partial volume correction; NonRSF: without partial volume correction; **signiﬁcant
diﬀerence (p < 0.0005) that survives Bonferroni correction for multiple comparisons. *signiﬁcant diﬀerence (p < 0.05) that does not survive Bonferroni correction.
The analysis was based on the longitudinal Knight ADRC data for stable amyloid negative participants.
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underlying implementation of the quantiﬁcation approach has to be
taken into account when interpreting the threshold, and one should not
simply adopt a threshold that was developed under method A and ap-
plying it to quantiﬁcation results obtained under method B even after
conversion into CL. These observations suggest there are challenges in
using the Centiloid approach to achieve the beneﬁts 2 and 3 summar-
ized at the beginning of our discussion and proposed in the original
Centiloid paper (Klunk et al., 2015). However, it should be pointed out
that part of the reason for the method dependent amyloid positivity
thresholds was that the methodology for deriving the thresholds was
driven more by the signal to noise ratio property of the amyloid burden
measurements rather than the underlying amount of pathology. The
current analysis suggests that the signal to noise ratio property is very
much method dependent, and as a simple linear transformation, one
should not expect the Centiloid conversion procedure to remove the
diﬀerences in signal to noise ratio property inherent in the quantiﬁca-
tion methods. Although this should be obvious for people familiar with
imaging quantiﬁcation and the implementation of the Centiloid ap-
proach, it may not be as evident for many people in the research
community using amyloid PET as a tool. On the other hand, if the goal
is to deﬁne physiologically meaningful amyloid positivity thresholds or
ranges of amyloid burdens, then one should use common Centiloid
values for the deﬁnition of the thresholds and ranges.
For longitudinal studies, the diﬀerent implementation of amyloid
PET imaging quantiﬁcation approaches led to diﬀerent sensitivity to
longitudinal changes even after applying the Centiloid conversion. This
diﬀerence in sensitivity resulted in diﬀerent sample sizes needed for
hypothetical clinical trials aiming at slowing amyloid accumulation. We
acknowledge the fact that some of the stable amyloid negative parti-
cipants, based on whom the intra-individual variability in amyloid
burden measurement was assessed, may express real albeit small ac-
cumulation of amyloid and therefore our intra-individual variability is
slightly biased toward a small positive change over time; however it
allowed us to provide a reasonable approximation of the noise in the
amyloid burden measurements in longitudinal studies as we used a very
conservative amyloid burden threshold and only included people who
remained amyloid negative at both visits.
The last beneﬁt of adopting the Centiloid approach was allowing for
a direct comparison of the characteristics of diﬀerent tracers (Klunk
et al., 2015), as the Centiloid approach converts all measurements into
the same scale. We believe this can be applied to the comparison of
diﬀerent quantiﬁcation as well, and as we observed in this study, dif-
ferent quantiﬁcation methods have diﬀerent sensitivity and speciﬁcity
properties. After converting to the common Centiloid scale, it is easier
to draw intuitive conclusions about the beneﬁts and drawbacks of the
diﬀerent approaches. For example, the RSF PVC technique consistently
reduced variability in the measurements and improved sensitivity to
longitudinal changes.
5. Conclusion
Using the Centiloid approach to convert quantitative amyloid
burden measurements into the Centiloid scale brings the amyloid
measurements into a comparable dynamic range. Meanwhile, the
Centiloid value derived from diﬀerent analysis techniques inherits most
of the inherent characteristics of the underlying analytic approaches,
and these diﬀerences are detectable in the analysis of large datasets and
lead to diﬀerent sensitivity to amyloid burden changes in longitudinal
studies. Because of these diﬀerences, the amyloid positivity thresholds
derived from diﬀerent analysis techniques diﬀer from one technique to
another. Therefore, when amyloid measurements obtained from dif-
ferent centers are combined for analysis, the impact of the diﬀerences in
underlying acquisition protocols and analysis techniques need to be
taken into consideration even after conversion into Centiloid scale.
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Fig. 4. The annualized rate of change as a function of baseline amyloid burden.
Dots are the raw data points, black solid lines are the average curve and red
dash lines are 95% CI (based on bootstrapping). Note the minimum of the black
curve (even the upper 95% CI curve) had a negative rate of change.
Fig. 5. Histogram of the distribution of cognitively normal participants in the ADRC cohort as a function of amyloid burden and the amyloid positivity thresholds
determined using the modiﬁed reliable worsening (RW) method (black) and the speciﬁcity method (green). The methods for PiB PET quantiﬁcation are SUVr analysis
with RSF partial volume correction using cerebellum cortex as the reference region and 30–60min post-injection time window (CL_3060_SUVr_RSF) (A); and SUVr
analysis without partial volume correction using brainstem as the reference region and 30–60min post-injection time window (CL_3060_SUVr_BS) (B).
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